{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:17:10Z","timestamp":1787807830012,"version":"build-2784847793"},"reference-count":242,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,17]],"date-time":"2027-07-17T00:00:00Z","timestamp":1815782400000},"content-version":"am","delay-in-days":319,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017453","name":"Institute for Prostate Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000056","name":"National Institute of Nursing Research","doi-asserted-by":"publisher","award":["U01CA233100"],"award-info":[{"award-number":["U01CA233100"]}],"id":[{"id":"10.13039\/100000056","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000056","name":"National Institute of Nursing Research","doi-asserted-by":"publisher","award":["R35CA253175"],"award-info":[{"award-number":["R35CA253175"]}],"id":[{"id":"10.13039\/100000056","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005895","name":"Fred Hutchinson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jconrel.2026.115182","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:03:13Z","timestamp":1784127793000},"page":"115182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Strategic engineering B cell immunity for cancer immunotherapy"],"prefix":"10.1016","volume":"397","author":[{"given":"Chengyi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrishi","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lam","family":"Trieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115182_bb0005","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0010","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.115182_bb0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115182_bb0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0025","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(25)00553-7","article-title":"Cancer vaccines and the future of immunotherapy","volume":"406","author":"Pail","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.115182_bb0030","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0035","first-page":"911","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat. Can."},{"key":"10.1016\/j.jconrel.2026.115182_bb0040","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115182_bb0045","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115182_bb0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev-immunol-020711-074934","article-title":"Immune regulatory function of B cells","volume":"30","author":"Mauri","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev.immunol.021908.132541","article-title":"B cell signaling and fate decision","volume":"28","author":"Kurosaki","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0060","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115182_bb0065","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115182_bb0070","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115182_bb0075","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.cell.2019.10.028","article-title":"B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer","volume":"179","author":"Hollern","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115182_bb0080","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3389\/fimmu.2017.01830","article-title":"Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?","volume":"8","author":"Colbeck","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0085","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41423-020-0457-0","article-title":"Tertiary lymphoid structures in cancer - considerations for patient prognosis","volume":"17","author":"Munoz-Erazo","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0090","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4049\/jimmunol.1701269","article-title":"Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity","volume":"200","author":"Engelhard","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0095","first-page":"747","article-title":"B lymphocytes and cancer: a love-hate relationship, Trends","volume":"2","author":"Yuen","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0100","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.201309-1611OC","article-title":"Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer","volume":"189","author":"Germain","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jconrel.2026.115182_bb0105","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-15-2762","article-title":"Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer","volume":"22","author":"Kroeger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0110","doi-asserted-by":"crossref","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115182_bb0115","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","article-title":"Tertiary lymphoid structures in anticancer immunity","volume":"24","author":"Teillaud","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0120","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.1021\/acsnano.3c13038","article-title":"Antigen-Clustered Nanovaccine Achieves Long-Term Tumor Remission by Promoting B\/CD 4 T Cell Crosstalk","volume":"18","author":"Li","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115182_bb0125","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jconrel.2020.08.021","article-title":"Antibody and antibody fragments for cancer immunotherapy","volume":"328","author":"Chen","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115182_bb0130","doi-asserted-by":"crossref","first-page":"7038","DOI":"10.1021\/acsnano.4c15113","article-title":"SARS-CoV-2 B Epitope-Guided Neoantigen NanoVaccines Enhance Tumor-Specific CD4\/CD8 T Cell Immunity through B Cell Antigen Presentation","volume":"19","author":"Li","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115182_bb0135","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41590-022-01248-5","article-title":"The humoral response and antibodies against SARS-CoV-2 infection","volume":"23","author":"Qi","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0140","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1385\/IR:22:2-3:199","article-title":"Studies of the humoral immune response","volume":"22","author":"Kelsoe","year":"2000","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0145","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"Adams","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0150","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","article-title":"Tertiary lymphoid structures and B cells: an intratumoral immunity cycle","volume":"56","author":"Fridman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115182_bb0155","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3389\/fimmu.2016.00401","article-title":"Understanding immune cells in tertiary lymphoid organ development: it is all starting to come together","volume":"7","author":"Jones","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109422","article-title":"Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts","volume":"36","author":"Rodriguez","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.jconrel.2026.115182_bb0165","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0170","unstructured":"J. Charles A Janeway, Paul Travers, Mark Walport, and Mark J Shlomchik., Immunobiology, 5th edition, 2001."},{"key":"10.1016\/j.jconrel.2026.115182_bb0175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41577-023-00897-3","article-title":"Memory B cells","volume":"24","author":"Inoue","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0180","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1182\/blood-2004-11-4284","article-title":"Identification and characterization of circulating human transitional B cells","volume":"105","author":"Sims","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115182_bb0185","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1600-065X.1997.tb00958.x","article-title":"The changing preference of T and B cells for partners as T-dependent antibody responses develop","volume":"156","author":"MacLennan","year":"1997","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jconrel.2026.115182_bb0190","first-page":"59","article-title":"Helper T cell-regulated B cell immunity","volume":"311","author":"McHeyzer-Williams","year":"2006","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0195","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1126\/science.272.5258.54","article-title":"Immunological memory and protective immunity: understanding their relation","volume":"272","author":"Ahmed","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115182_bb0200","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.immuni.2016.09.001","article-title":"Germinal center B cell dynamics","volume":"45","author":"Mesin","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115182_bb0205","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/cid\/ciy142","article-title":"Protecting the community through child vaccination","volume":"67","author":"Anderson","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2026.115182_bb0210","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/icb.2017.6","article-title":"Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells","volume":"95","author":"Ochoa","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0220","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-12-0989","article-title":"GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab","volume":"19","author":"Gerdes","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0225","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115182_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/genes15070903","article-title":"A Comprehensive Review of HER2 in Cancer Biology and Therapeutics","volume":"15","author":"Cheng","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jconrel.2026.115182_bb0235","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1158\/1078-0432.CCR-03-0549","article-title":"A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies","volume":"10","author":"Spiridon","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0240","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-4615-0081-0_21","article-title":"Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4","volume":"532","author":"Albanell","year":"2003","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0245","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41588-018-0339-x","article-title":"Landscape of B cell immunity and related immune evasion in human cancers","volume":"51","author":"Hu","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jconrel.2026.115182_bb0250","doi-asserted-by":"crossref","first-page":"eabl9171","DOI":"10.1126\/sciadv.abl9171","article-title":"Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy","volume":"8","author":"Cao","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115182_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120601","article-title":"Enhancing antibody-dependent cellular phagocytosis by Re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes","volume":"268","author":"Li","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115182_bb0260","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41568-019-0210-0","article-title":"Context-dependent roles of complement in cancer","volume":"19","author":"Roumenina","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0265","first-page":"1091","article-title":"Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth, Cancer","volume":"7","author":"Roumenina","year":"2019","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0270","doi-asserted-by":"crossref","first-page":"10346","DOI":"10.1038\/ncomms10346","article-title":"C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation","volume":"7","author":"Bulla","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115182_bb0275","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/ni.1655","article-title":"Modulation of the antitumor immune response by complement","volume":"9","author":"Markiewski","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0280","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cell.2020.02.015","article-title":"Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity","volume":"180","author":"Lu","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115182_bb0285","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41586-020-03144-0","article-title":"IgA transcytosis and antigen recognition govern ovarian cancer immunity","volume":"591","author":"Biswas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115182_bb0290","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41591-018-0309-y","article-title":"Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG","volume":"25","author":"Gu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115182_bb0295","doi-asserted-by":"crossref","first-page":"1671839","DOI":"10.3389\/fimmu.2025.1671839","article-title":"Unraveling the dual roles of tumor-infiltrating antibodies in solid tumors: friend or foe in the tumor microenvironment?","volume":"16","author":"Miao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0300","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1172\/JCI65579","article-title":"IgG4 subclass antibodies impair antitumor immunity in melanoma","volume":"123","author":"Karagiannis","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115182_bb0305","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000661","article-title":"An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy","volume":"8","author":"Wang","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0310","first-page":"221","article-title":"IgA, IgA receptors, and their anti-inflammatory properties","volume":"382","author":"Mkaddem","year":"2014","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0315","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.autrev.2012.10.011","article-title":"Anti-inflammatory role of the IgA Fc receptor (CD89): from autoimmunity to therapeutic perspectives","volume":"12","author":"Ben Mkaddem","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jconrel.2026.115182_bb0320","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.immuni.2015.01.009","article-title":"Antibody effector functions mediated by Fcgamma-receptors are compromised during persistent viral infection","volume":"42","author":"Wieland","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115182_bb0325","first-page":"248","article-title":"Prognostic implications of circulating anti-p53 antibodies in lung cancer\u2014a review","volume":"18","author":"Kumar","year":"2009","journal-title":"Eur. J. Cancer Care (Engl)"},{"key":"10.1016\/j.jconrel.2026.115182_bb0330","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.yexcr.2013.03.005","article-title":"B cells and their mediators as targets for therapy in solid tumors","volume":"319","author":"Gunderson","year":"2013","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0335","doi-asserted-by":"crossref","first-page":"1455602","DOI":"10.3389\/fimmu.2024.1455602","article-title":"Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers","volume":"15","author":"Montero-Calle","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0340","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1016\/j.ajpath.2014.07.027","article-title":"Antiphospholipid antibodies promote tissue factor-dependent angiogenic switch and tumor progression","volume":"184","author":"Wu","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0345","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/CMR.0b013e3283426805","article-title":"Autoantibodies against cell surface GRP78 promote tumor growth in a murine model of melanoma","volume":"21","author":"de Ridder","year":"2011","journal-title":"Melanoma Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0350","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1073\/pnas.1916833117","article-title":"Immunity against cancer cells may promote their proliferation and metastasis","volume":"117","author":"Lin","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115182_bb0355","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41586-025-09188-4","article-title":"Humoral determinants of checkpoint immunotherapy","volume":"644","author":"Dai","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115182_bb0360","first-page":"43","article-title":"Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction","volume":"4","author":"Qiu","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.jconrel.2026.115182_bb0365","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115182_bb0370","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/imr.12859","article-title":"The role of B cell antigen presentation in the initiation of CD4+ T cell response","volume":"296","author":"Hua","year":"2020","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jconrel.2026.115182_bb0375","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/intimm\/13.12.1583","article-title":"Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations","volume":"13","author":"Rivera","year":"2001","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0380","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1158\/2326-6066.CIR-17-0075","article-title":"Antigen-presenting intratumoral B cells affect CD4(+) TIL phenotypes in non-small cell lung cancer patients","volume":"5","author":"Bruno","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0385","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/2326-6066.CIR-20-0949","article-title":"CD86(+) antigen-presenting B cells are increased in cancer, localize in tertiary lymphoid structures, and induce specific t-cell responses","volume":"9","author":"Wennhold","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0390","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","article-title":"Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses","volume":"184","author":"Cui","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115182_bb0395","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1158\/1078-0432.CCR-12-0234","article-title":"CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer","volume":"18","author":"Nielsen","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0400","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115182_bb0405","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1182\/blood.V99.9.3319","article-title":"Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application","volume":"99","author":"von Bergwelt-Baildon","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115182_bb0410","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI119822","article-title":"CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy","volume":"100","author":"Schultze","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115182_bb0415","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.4049\/jimmunol.170.3.1191","article-title":"Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs","volume":"170","author":"Gnjatic","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0420","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1074-7613(02)00274-1","article-title":"Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation","volume":"16","author":"Mizoguchi","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115182_bb0425","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/ni833","article-title":"B cells regulate autoimmunity by provision of IL-10","volume":"3","author":"Fillatreau","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0430","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0008-8749(81)90048-4","article-title":"Antitumor immunity in B-lymphocyte-deprived mice. II. In vitro studies","volume":"65","author":"Brodt","year":"1981","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0435","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/imm.12389","article-title":"Contact dependent suppression of CD4 T cell activation and proliferation by B cells activated through IgD cross-linking","volume":"144","author":"Preciado-Llanes","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.jconrel.2026.115182_bb0440","doi-asserted-by":"crossref","first-page":"14803","DOI":"10.18632\/oncotarget.22976","article-title":"Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1\/PD-L1 pathway","volume":"9","author":"Zhao","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2026.115182_bb0445","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1038\/ncomms6997","article-title":"PD-L1hi B cells are critical regulators of humoral immunity","volume":"6","author":"Khan","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115182_bb0450","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005644","article-title":"Activated B cells suppress T-cell function through metabolic competition","volume":"10","author":"Imahashi","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0455","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ajt.15546","article-title":"Antigen-dependent interactions between regulatory B cells and T cells at the T:B border inhibit subsequent T cell interactions with DCs","volume":"20","author":"Mohib","year":"2020","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jconrel.2026.115182_bb0460","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.4049\/jimmunol.167.2.1081","article-title":"Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice","volume":"167","author":"Tian","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0465","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1158\/0008-5472.CAN-12-3450","article-title":"Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells","volume":"73","author":"Lindner","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0470","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nri3857","article-title":"Antibody-independent functions of B cells: a focus on cytokines","volume":"15","author":"Shen","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0475","article-title":"B cells promote tumor progression via STAT3 regulated-angiogenesis","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2026.115182_bb0480","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.coi.2008.03.003","article-title":"Cytokine-producing B lymphocytes-key regulators of immunity","volume":"20","author":"Lund","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0485","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaut.2014.04.001","article-title":"The immune potential and immunopathology of cytokine-producing B cell subsets: a comprehensive review","volume":"55","author":"Bao","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jconrel.2026.115182_bb0490","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1191\/0961203303lu338oa","article-title":"Assessment of Be1 and Be2 cells in systemic lupus erythematosus indicates elevated interleukin-10 producing CD5+ B cells","volume":"12","author":"Amel Kashipaz","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.jconrel.2026.115182_bb0495","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.immuni.2019.04.004","article-title":"T-bet transcription factor promotes antibody-secreting cell differentiation by limiting the inflammatory effects of IFN-gamma on B cells","volume":"50","author":"Stone","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115182_bb0500","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41467-021-22458-9","article-title":"B1a and B2 cells are characterized by distinct CpG modification states at DNMT3A-maintained enhancers","volume":"12","author":"Mahajan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115182_bb0505","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/1078-0432.CCR-16-0081","article-title":"A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases","volume":"23","author":"Montfort","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0510","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1038\/s41467-019-12160-2","article-title":"B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma","volume":"10","author":"Griss","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115182_bb0515","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.4049\/jimmunol.0901066","article-title":"Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21","volume":"183","author":"Hagn","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0520","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1158\/1078-0432.CCR-11-0207","article-title":"Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression","volume":"17","author":"Li","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0525","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.immuni.2014.10.016","article-title":"Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation","volume":"41","author":"Matsumoto","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115182_bb0530","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature12979","article-title":"IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases","volume":"507","author":"Shen","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115182_bb0535","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3389\/fimmu.2018.01364","article-title":"Transforming growth factor-beta and interleukin-10 synergistically regulate humoral immunity via modulating metabolic signals","volume":"9","author":"Komai","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0540","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1172\/JCI85113","article-title":"Human regulatory B cells in health and disease: therapeutic potential","volume":"127","author":"Mauri","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115182_bb0545","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxac048","article-title":"Suppressive mechanisms of regulatory B cells in mice and humans","volume":"35","author":"Matsumura","year":"2023","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0550","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1111\/ajt.16772","article-title":"Properties of regulatory B cells regulating B cell targets","volume":"21","author":"Fu","year":"2021","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jconrel.2026.115182_bb0555","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","article-title":"STING-induced regulatory B cells compromise NK function in cancer immunity","volume":"610","author":"Li","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115182_bb0560","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12282-018-0910-4","article-title":"Coexistence of regulatory B cells and regulatory T cells in tumor-infiltrating lymphocyte aggregates is a prognostic factor in patients with breast cancer","volume":"26","author":"Ishigami","year":"2019","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0565","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1007\/s13277-015-4538-0","article-title":"Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients","volume":"37","author":"Wei","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0570","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-10-4316","article-title":"Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells","volume":"71","author":"Olkhanud","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0575","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41586-021-04082-1","article-title":"B cell-derived GABA elicits IL-10(+) macrophages to limit anti-tumour immunity","volume":"599","author":"Zhang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115182_bb0580","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1189\/jlb.0413240","article-title":"The role of viruses in autoreactive B cell activation within tertiary lymphoid structures in autoimmune diseases","volume":"94","author":"Lucchesi","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0585","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nri3700","article-title":"Ectopic lymphoid-like structures in infection, cancer and autoimmunity","volume":"14","author":"Pitzalis","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0590","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Sautes-Fridman","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0595","first-page":"794","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat. Can."},{"key":"10.1016\/j.jconrel.2026.115182_bb0600","doi-asserted-by":"crossref","first-page":"6391","DOI":"10.1158\/0008-5472.CAN-11-0952","article-title":"Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer","volume":"71","author":"de Chaisemartin","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0605","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","article-title":"Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells","volume":"74","author":"Goc","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0610","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-18-1481","article-title":"Prognostic significance of tumor-infiltrating b cells and plasma cells in human cancer","volume":"24","author":"Wouters","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0615","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.ccell.2024.07.006","article-title":"CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis","volume":"42","author":"Zhang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.115182_bb0620","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002101","article-title":"PD-1(+)CXCR5(-)CD4(+) Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma","volume":"9","author":"Li","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0625","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002273","article-title":"Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma","volume":"9","author":"Lynch","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0630","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-08-2360","article-title":"Regulatory T cells recruited through CCL22\/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome","volume":"69","author":"Gobert","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0635","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12885-015-1116-1","article-title":"Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients","volume":"15","author":"Figenschau","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0640","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/ni.3290","article-title":"Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma","volume":"16","author":"Finkin","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0645","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.immuni.2015.08.006","article-title":"Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses","volume":"43","author":"Joshi","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115182_bb0650","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2025.12.011","article-title":"B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity","volume":"44","author":"Chen","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.115182_bb0655","first-page":"215","article-title":"Host tissue determinants of tumour immunity","volume":"19","author":"Salmon","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0660","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(67)92837-1","article-title":"Immunological aspects of malignant disease","volume":"1","author":"Burnet","year":"1967","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.115182_bb0665","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115182_bb0670","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115182_bb0675","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jconrel.2023.11.051","article-title":"OX40L-expressing M1-like macrophage exosomes for cancer immunotherapy","volume":"365","author":"Yu","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115182_bb0680","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-023-01844-5","article-title":"The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0685","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-026-01322-1","article-title":"A guide to CAR T cell therapies: development, current status and future prospects","author":"Rafei","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0690","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0695","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-immunol-030409-101216","article-title":"Early events in B cell activation","volume":"28","author":"Harwood","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0700","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nri3728","article-title":"Phenotypic models of T cell activation","volume":"14","author":"Lever","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0705","doi-asserted-by":"crossref","DOI":"10.1111\/imr.70004","article-title":"Signaling activation and modulation in extrafollicular B cell responses","volume":"330","author":"Staniek","year":"2025","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jconrel.2026.115182_bb0710","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","article-title":"T cell exhaustion","volume":"42","author":"Baessler","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0715","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.immuni.2020.11.006","article-title":"Germinal center and extrafollicular B cell responses in vaccination, immunity, and autoimmunity","volume":"53","author":"Elsner","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115182_bb0720","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2026.115182_bb0725","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12016-021-08918-6","article-title":"The role of autoantibody testing in modern personalized medicine","volume":"63","author":"Kayser","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0730","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8(+) T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0735","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41419-025-08254-z","article-title":"Targeting tumour-infiltrating B cells: mechanisms and advances in cancer therapy","volume":"17","author":"Yang","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2026.115182_bb0740","doi-asserted-by":"crossref","first-page":"eadj4857","DOI":"10.1126\/science.adj4857","article-title":"A blueprint for tumor-infiltrating B cells across human cancers","volume":"384","author":"Ma","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115182_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2024.09.011","article-title":"A pan-cancer single-cell RNA-seq atlas of intratumoral B cells","volume":"42","author":"Fitzsimons","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.115182_bb0750","first-page":"857","article-title":"Dual targeting of PI3K\u03b3 and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer","volume":"7","author":"Li","year":"2026","journal-title":"Nat. Can."},{"key":"10.1016\/j.jconrel.2026.115182_bb0755","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00262-025-03973-w","article-title":"Revealing the role of regulatory b cells in cancer: development, function and treatment significance","volume":"74","author":"Ye","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2026.115182_bb0760","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-023-00568-6","article-title":"PPAR\u03b4 inhibition blocks the induction and function of tumor-induced IL-10+ regulatory B cells and enhances cancer immunotherapy","volume":"9","author":"Chen","year":"2023","journal-title":"Cell Discov."},{"key":"10.1016\/j.jconrel.2026.115182_bb0765","doi-asserted-by":"crossref","first-page":"eadh1315","DOI":"10.1126\/scitranslmed.adh1315","article-title":"Dysfunctional CD11c(-)CD21(-) extrafollicular memory B cells are enriched in the periphery and tumors of patients with cancer","volume":"17","author":"Ruffin","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115182_bb0770","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","article-title":"Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115182_bb0775","doi-asserted-by":"crossref","first-page":"1275378","DOI":"10.3389\/fimmu.2023.1275378","article-title":"Of mice and lymphoid aggregates: modeling tertiary lymphoid structures in cancer","volume":"14","author":"Vaccaro","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2026.115182_bb0785","doi-asserted-by":"crossref","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jconrel.2026.115182_bb0790","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41467-019-08534-1","article-title":"Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy","volume":"10","author":"Rosato","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115182_bb0795","article-title":"IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy","volume":"5","author":"Lee","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.jconrel.2026.115182_bb0800","doi-asserted-by":"crossref","unstructured":"W.B. Coley, The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893, Clin Orthop Relat Res, (1991) 3-11.","DOI":"10.1097\/00003086-199101000-00002"},{"key":"10.1016\/j.jconrel.2026.115182_bb0805","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0810","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jconrel.2023.02.015","article-title":"Vaccine-like nanomedicine for cancer immunotherapy","volume":"355","author":"Yi","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115182_bb0815","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju268","article-title":"Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer","volume":"106","author":"Fong","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2026.115182_bb0820","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0825","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41551-019-0436-x","article-title":"Engineering patient-specific cancer immunotherapies","volume":"3","author":"Scheetz","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.115182_bb0830","doi-asserted-by":"crossref","first-page":"eadx8303","DOI":"10.1126\/sciadv.adx8303","article-title":"B cell-reactive neoantigens boost antitumor immunity","volume":"11","author":"Kim","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115182_bb0835","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2217\/fon-2020-0224","article-title":"B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine","volume":"16","author":"Kaumaya","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0840","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.939356","article-title":"Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers","volume":"12","author":"Ede","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0845","doi-asserted-by":"crossref","first-page":"1382236","DOI":"10.3389\/fimmu.2024.1382236","article-title":"Activated B-Cells enhance epitope spreading to support successful cancer immunotherapy","volume":"15","author":"Kellermann","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0850","first-page":"331","article-title":"New concepts in tumor antigens: their significance in future immunotherapies for tumors","volume":"2","author":"Yang","year":"2005","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0855","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature10755","article-title":"Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting","volume":"482","author":"Matsushita","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115182_bb0860","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070984","article-title":"Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?","volume":"11","author":"Al-Khadairi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2026.115182_bb0865","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020779","article-title":"Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer","volume":"22","author":"Pallerla","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115182_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100361","article-title":"Vaccination against Her-2\/neu, with focus on peptide-based vaccines","volume":"7","author":"Tobias","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.jconrel.2026.115182_bb0875","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: a multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115182_bb0880","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10555-013-9444-6","article-title":"Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis","volume":"32","author":"Beauchemin","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.jconrel.2026.115182_bb0885","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.cmr.0000222588.22493.3f","article-title":"Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens","volume":"16","author":"Lim","year":"2006","journal-title":"Melanoma Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb0890","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12885-017-3098-7","article-title":"Enhanced and long term immunogenicity of a Her-2\/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide","volume":"17","author":"Tobias","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb0895","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cmdc.201700646","article-title":"A synthetic MUC1 anticancer vaccine containing mannose ligands for targeting macrophages and dendritic cells","volume":"13","author":"Glaffig","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jconrel.2026.115182_bb0900","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/cmdc.201700387","article-title":"Immunization with a synthetic human MUC1 glycopeptide vaccine against tumor-associated MUC1 breaks tolerance in human MUC1 transgenic mice","volume":"12","author":"Stergiou","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jconrel.2026.115182_bb0905","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1002\/anie.201104529","article-title":"Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues","volume":"50","author":"Gaidzik","year":"2011","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2026.115182_bb0910","doi-asserted-by":"crossref","first-page":"12418","DOI":"10.18632\/oncotarget.2628","article-title":"Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer","volume":"5","author":"Femel","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2026.115182_bb0915","doi-asserted-by":"crossref","first-page":"12532","DOI":"10.1073\/pnas.1610258113","article-title":"Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity","volume":"113","author":"Wentink","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115182_bb0920","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202411361","article-title":"Personalized Multi-epitope nanovaccine unlocks B cell-mediated multiple pathways of antitumor immunity","volume":"37","author":"Yan","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.115182_bb0925","doi-asserted-by":"crossref","first-page":"eabm7833","DOI":"10.1126\/sciadv.abm7833","article-title":"Multiepitope supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses","volume":"8","author":"Wu","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115182_bb0930","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0935","author":"Moderna"},{"key":"10.1016\/j.jconrel.2026.115182_bb0940","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.115182_bb0945","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115182_bb0950","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115182_bb0955","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/s41467-025-57149-2","article-title":"LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment","volume":"16","author":"Xue","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115182_bb0960","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41551-025-01344-5","article-title":"Small circular RNAs as vaccines for cancer immunotherapy","volume":"9","author":"Zhang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.115182_bb0965","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12033-012-9598-4","article-title":"Construction and characterization of virus-like particles: a review","volume":"53","author":"Zeltins","year":"2013","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0970","doi-asserted-by":"crossref","first-page":"1106767","DOI":"10.3389\/fbioe.2022.1106767","article-title":"Virus-like nanoparticles as a theranostic platform for cancer","volume":"10","author":"Kim","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0975","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1579","article-title":"Virus-like particles for vaccination against cancer","volume":"12","author":"Mohsen","year":"2020","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.115182_bb0980","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115182_bb0985","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1408749","article-title":"Virus-like particle display of HER2 induces potent anti-cancer responses","volume":"7","author":"Palladini","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2026.115182_bb0990","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2221859120","article-title":"Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis","volume":"120","author":"Chung","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115182_bb0995","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1038\/s41467-025-60239-w","article-title":"A cowpea mosaic virus adjuvant conjugated to liposomes loaded with tumor cell lysates as an ovarian cancer vaccine","volume":"16","author":"Zhao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115182_bb1000","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41591-020-0753-3","article-title":"Engineered immunogen binding to alum adjuvant enhances humoral immunity","volume":"26","author":"Moyer","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115182_bb1005","doi-asserted-by":"crossref","first-page":"102415","DOI":"10.1016\/j.xcrm.2025.102415","article-title":"Super-adjuvant nanoparticles for platform cancer vaccination","volume":"6","author":"Kane","year":"2026","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.jconrel.2026.115182_bb1010","doi-asserted-by":"crossref","first-page":"eadw0797","DOI":"10.1126\/sciadv.adw0797","article-title":"Temporally programmed STING nanoadjuvant delivery unlocks synergistic chemotherapy-induced antitumor immunity","volume":"11","author":"Yang","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115182_bb1015","doi-asserted-by":"crossref","first-page":"30701","DOI":"10.1021\/acsnano.4c09902","article-title":"Spleen-targeted mRNA vaccine doped with manganese adjuvant for robust anticancer immunity in vivo","volume":"18","author":"Luo","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115182_bb1020","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102623","article-title":"Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines","volume":"36","author":"Zhou","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2026.115182_bb1025","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.111209","article-title":"Combining anti-checkpoint immunotherapies and cancer vaccines as a novel strategy in oncological therapy: A review","volume":"86","author":"Ghaneialvar","year":"2025","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb1030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105154","article-title":"T cell exhaustion initiates tertiary lymphoid structures and turbocharges cancer-immunity cycle","volume":"104","author":"Lin","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jconrel.2026.115182_bb1035","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1158\/1078-0432.CCR-20-3742","article-title":"Clinical and immunologic responses to a b-cell epitope vaccine in patients with HER2\/neu-overexpressing advanced gastric cancer-results from phase Ib trial IMU.ACS.001","volume":"27","author":"Wiedermann","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb1040","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1158\/1078-0432.CCR-18-2867","article-title":"Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial","volume":"25","author":"Mittendorf","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb1045","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115182_bb1050","doi-asserted-by":"crossref","first-page":"28184","DOI":"10.1021\/acsami.4c04385","article-title":"Polymer micropatches as B-cell engagers","volume":"16","author":"Prakash","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2026.115182_bb1055","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136417","article-title":"Effects of B cell-activating factor on tumor immunity","volume":"5","author":"Yarchoan","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jconrel.2026.115182_bb1060","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1158\/0008-5472.CAN-14-0708","article-title":"Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response","volume":"74","author":"Deng","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb1065","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/intimm\/dxv027","article-title":"Signals controlling the development and activity of regulatory B-lineage cells","volume":"27","author":"Baba","year":"2015","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb1070","article-title":"Nanosensitizer for cancer radioimmunotherapy via anti-IL-35 blockade boosted innate immunity activation","volume":"12","author":"Zheng","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.jconrel.2026.115182_bb1075","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1038\/s41388-018-0668-3","article-title":"BTK signaling drives CD1d(hi)CD5(+) regulatory B-cell differentiation to promote pancreatic carcinogenesis","volume":"38","author":"Das","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2026.115182_bb1080","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/s41467-021-22230-z","article-title":"The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5","volume":"12","author":"Radomir","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115182_bb1085","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/nm.3680","article-title":"Regulatory B cells are induced by gut microbiota-driven interleukin-1beta and interleukin-6 production","volume":"20","author":"Rosser","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115182_bb1090","doi-asserted-by":"crossref","first-page":"10416","DOI":"10.1038\/s41467-025-66581-3","article-title":"Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinoma","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115182_bb1095","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1073\/pnas.0606697104","article-title":"Lymphotoxin beta receptor signaling is required for inflammatory lymphangiogenesis in the thyroid","volume":"104","author":"Furtado","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.115182_bb1100","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4049\/jimmunol.169.1.424","article-title":"Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis","volume":"169","author":"Luther","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb1105","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1084\/jem.20181216","article-title":"Type I interferon induces CXCL13 to support ectopic germinal center formation","volume":"216","author":"Denton","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115182_bb1110","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41467-017-00504-9","article-title":"Interactions between fibroblastic reticular cells and B cells promote mesenteric lymph node lymphangiogenesis","volume":"8","author":"Dubey","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115182_bb1115","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1074-7613(02)00423-5","article-title":"The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways","volume":"17","author":"Dejardin","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115182_bb1120","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/ni.3836","article-title":"De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors","volume":"18","author":"Johansson-Percival","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb1125","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41467-020-14425-7","article-title":"Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors","volume":"11","author":"Huang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115182_bb1130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.04.010","article-title":"Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma","volume":"41","author":"Ramachandran","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.115182_bb1135","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1016\/j.ymthe.2023.06.015","article-title":"LIGHT\/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment","volume":"31","author":"Zhang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115182_bb1140","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature10540","article-title":"Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules","volume":"479","author":"Moussion","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115182_bb1145","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.4049\/jimmunol.1300872","article-title":"High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin beta-producing dendritic cells in human breast cancer","volume":"191","author":"Martinet","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb1150","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1322238","article-title":"Tbet and IL-36gamma cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment","volume":"6","author":"Weinstein","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2026.115182_bb1155","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00262-018-2259-0","article-title":"Association of IL-36gamma with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer","volume":"68","author":"Weinstein","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2026.115182_bb1160","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1158\/0008-5472.CAN-12-1912","article-title":"T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion","volume":"72","author":"Hindley","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb1165","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1158\/2326-6066.CIR-17-0131","article-title":"Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction","volume":"5","author":"Colbeck","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2026.115182_bb1170","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1021\/acsnano.2c09619","article-title":"Nanovaccines fostering tertiary lymphoid structure to attack mimicry nasopharyngeal carcinoma","volume":"17","author":"Wen","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115182_bb1175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.immuni.2021.12.007","article-title":"TGF-beta-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures","volume":"55","author":"Chaurio","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115182_bb1180","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41467-021-27833-0","article-title":"Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kalpha\/beta\/delta treatment","volume":"13","author":"Qi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115182_bb1185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001906","article-title":"STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment","volume":"9","author":"Chelvanambi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115182_bb1190","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1038\/s41467-021-24347-7","article-title":"Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma","volume":"12","author":"van Hooren","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115182_bb1195","doi-asserted-by":"crossref","first-page":"2093054","DOI":"10.1080\/2162402X.2022.2093054","article-title":"Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation","volume":"11","author":"He","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2026.115182_bb1200","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fimmu.2017.00767","article-title":"Tumor-associated tertiary lymphoid structures: gene-expression profiling and their bioengineering","volume":"8","author":"Zhu","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb1205","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3389\/fimmu.2018.01609","article-title":"Induction of tertiary lymphoid structures with antitumor function by a lymph node-derived stromal cell line","volume":"9","author":"Zhu","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115182_bb1210","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.11.003","article-title":"Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer","volume":"54","author":"Overacre-Delgoffe","year":"2021","journal-title":"Immunity"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:17:22Z","timestamp":1787804242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926005857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":242,"alternative-id":["S0168365926005857"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115182","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategic engineering B cell immunity for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115182"}}